• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 8th June 2016

New Publication: EuroQol Protocols for Time Trade-Off Valuation of Health States

OHE’s Koonal Shah is co-author of a new paper examining EuroQol protocols for time trade-off valuation of health states. Time trade-off (TTO) is a stated preference technique that can be used to obtain values for health states for use in…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email
8-June-TTO-figure

OHE’s Koonal Shah is co-author of a new paper examining EuroQol protocols for time trade-off valuation of health states.

Time trade-off (TTO) is a stated preference technique that can be used to obtain values for health states for use in the economic evaluation of health technologies. Several variants of TTO are available. Protocols for implementing TTO vary in several ways, such as the procedure for ‘iterating’ towards a point of indifference, and the method for obtaining values for health states considered to be ‘worse than dead’. The use of different TTO variants leads to two practical problems: incomparability across studies and difficulty in choosing among the variants.

The EuroQol Group, an international, multi-disciplinary network of researchers, has developed three standardised TTO protocols for the valuation of health states described by its EQ-5D instruments. One of those protocols, known as the EQ-VT protocol, is recommended for the valuation of EQ-5D-5L health states, and was used in OHE’s EQ-5D-5L value set for England study.

Screenshot from the EQ-VT TTO protocol

Source: EuroQol Valuation Technology; ©EuroQol Research Foundation

Just published in PharmacoEconomics is an open access article that explains how the TTO technique works and describes the EuroQol protocols for TTO valuations. The paper is authored by Mark Oppe, Juan Manuel Ramos‐Goñi (both of the EuroQol Research Foundation), Kim Rand-Hendriksen (Akershus University Hospital and the University of Oslo), Nan Luo (National University of Singapore) and OHE’s Koonal Shah.

Access the paper here (available for free download).

Preparation of the paper was partially supported by the EuroQol Research Foundation. However, the views expressed do not necessarily reflect the views of the EuroQol Research Foundation.

Cite as:

Oppe, M., Rand-Hendriksen, K., Shah, K., Ramos‐Goñi, J.M. and Luo, N., 2016. EuroQol protocols for time trade-off valuation of health outcomes. PharmacoEconomics. DOI: 10.1007/s40273-016-0404-1

Related publications by OHE staff:

Devlin, N., Buckingham, K., Shah, K.K., Tsuchiya, A., Tilling, C., Wilkinson, G. and van Hout, B., 2013. A comparison of alternative variants of the lead and lag time TTO. Health Economics, 22(5), pp.517-532.

Devlin, N.J. and Krabbe, P.F., 2013. The development of new research methods for the valuation of EQ-5D-5L. European Journal of Health Economics, 14(Suppl 1), pp.S1-S3.

Shah, K., Mulhern, B., Longworth, L., Janssen, M.F., 2016. An empirical study of two alternative comparators for use in time trade-off studies. Value in Health, 19, pp.53-59.

 

  • EQ-5D and PROMs
  • Measuring and Valuing Outcomes
  • External Publications

Related News

  • News
  • September 2020

Establishing a Reasonable Price for an Orphan Drug

Read more
  • News
  • April 2020

Augmenting Cost-Effectiveness Analysis for Uncertainty: The Implications for Value Assessment—Rationale and Empirical Support

Read more
  • News
  • April 2020

Financing and Scaling Innovation for the COVID Fight: A Closer Look at Demand-Side Incentives for a Vaccine

Read more
  • News
  • February 2020

Unpacking the Black Box of Payer Policy: A Demand-Side Approach for Equitable Uptake of Cost-Effective Health Innovation

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!